Neurotrophin gene augmentation by electrotransfer to improve cochlear implant hearing outcomes

Simple item page
dc.contributor.authorPinyon, Jeremy
dc.contributor.authorvon Jonquieres, Georg
dc.contributor.authorCrawford, Edward
dc.contributor.authorDuxbury, Mayryl
dc.contributor.authorAl Abed, Amr
dc.contributor.authorLovell, Nigel
dc.contributor.authorKlugmann, Matthias
dc.contributor.authorWise, Andrew
dc.contributor.authorFallon, James
dc.contributor.authorShepherd, Robert
dc.contributor.authorBirman, Catherine
dc.contributor.authorLai, Waikong
dc.contributor.authorMcAlpine, David
dc.contributor.authorMcMahon, Catherine
dc.contributor.authorCarter, Paul
dc.contributor.authorEnke, Ya Lang
dc.contributor.authorPatrick, James
dc.contributor.authorSchilder, Anne
dc.contributor.authorMarie, Corinne
dc.contributor.authorScherman, Daniel
dc.contributor.authorHousley, Gary
dc.date.accessioned2019-08-26T01:21:06Z
dc.date.available2019-08-26T01:21:06Z
dc.date.issued2019-07
dc.description.abstractThis Review outlines the development of DNA-based therapeutics for treatment of hearing loss, and in particular, considers the potential to utilize the properties of recombinant neurotrophins to improve cochlear auditory (spiral ganglion) neuron survival and repair. This potential to reduce spiral ganglion neuron death and indeed re-grow the auditory nerve fibres has been the subject of considerable pre-clinical evaluation over decades with the view of improving the neural interface with cochlear implants. This provides the context for discussion about the development of a novel means of using cochlear implant electrode arrays for gene electrotransfer. Mesenchymal cells which line the cochlear perilymphatic compartment can be selectively transfected with (naked) plasmid DNA using array - based gene electrotransfer, termed 'close-field electroporation'. This technology is able to drive expression of brain derived neurotrophic factor (BDNF) in the deafened guinea pig model, causing re-growth of the spiral ganglion peripheral neurites towards the mesenchymla cells, and hence into close proximity with cochlear implant electrodes within scala tympani. This was associated with functional enhancement of the cochlear implant neural interface (lower neural recruitment thresholds and expanded dynamic range, measured using electrically - evoked auditory brainstem responses). The basis for the efficiency of close-field electroporation arises from the compression of the electric field in proximity to the ganged cochlear implant electrodes. The regions close to the array with highest field strength corresponded closely to the distribution of bioreporter cells (adherent human embryonic kidney (HEK293)) expressing green fluorescent reporter protein (GFP) following gene electrotransfer. The optimization of the gene electrotransfer parameters using this cell-based model correlated closely with in vitro and in vivo cochlear gene delivery outcomes. The migration of the cochlear implant electrode array-based gene electrotransfer platform towards a clinical trial for neurotrophin-based enhancement of cochlear implants is supported by availability of a novel regulatory compliant mini-plasmid DNA backbone (pFAR4; plasmid Free of Antibiotic Resistance v.4) which could be used to package a 'humanized' neurotrophin expression cassette. A reporter cassette packaged into pFAR4 produced prominent GFP expression in the guinea pig basal turn perilymphatic scalae. More broadly, close-field gene electrotransfer may lend itself to a spectrum of potential DNA therapeutics applications benefitting from titratable, localised, delivery of naked DNA, for gene augmentation, targeted gene regulation, or gene substitution strategies.en_US
dc.description.sponsorshipSupported by funding from the Australian Research Council (ARC), grants (ARC DP151014754, ARC LP0992098, ARC LP140101008), the Garnett Passe and Rodney Williams Memorial Foundation, and the National Health and Medical Research Council (NHMRC) grants APP1091646, APP1122055 and GNT1142910. The research was supported by collaborative research funding from Cochlear Ltd.en_US
dc.identifier.citationPinyon, J. L., G. von Jonquieres, E. N. Crawford, M. Duxbury, A. Al Abed, N. H. Lovell, M. Klugmann, A. K. Wise, J. B. Fallon, R. K. Shepherd, C. S. Birman, W. Lai, D. McAlpine, C. McMahon, P. M. Carter, Y. L. Enke, J. F. Patrick, A. G. M. Schilder, C. Marie, D. Scherman, and G. D. Housley. 2019. Neurotrophin gene augmentation by electrotransfer to improve cochlear implant hearing outcomes. Hearing Research. 380: 137-149.en_US
dc.identifier.issn0378-5955
dc.identifier.urihttp://repository.bionicsinstitute.org:8080/handle/123456789/360
dc.language.isoenen_US
dc.publisherElsevier, Inc.en_US
dc.subjectBrain derived neurotrophic factoren_US
dc.subjectNeurotrophin-3en_US
dc.subjectBionic array directed gene electrotransferen_US
dc.subjectAuditory nerve fibre regenerationen_US
dc.subjectGene therapyen_US
dc.subjectSensorineural hearing lossen_US
dc.titleNeurotrophin gene augmentation by electrotransfer to improve cochlear implant hearing outcomesen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2019_Pinyon_Neurotrophin.pdf
Size:
56.71 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
BI publications